Predicting the COVID-19 Pandemic Impact on Clinical Trial Recruitment

被引:5
|
作者
Best, Nicky [1 ]
Perevozskaya, Inna [2 ]
Lunn, Dave [1 ]
Archer, Graeme [3 ]
Euesden, Jack [4 ]
Fillmore, Christina [5 ]
Sherina, Valeriia [6 ]
Thompson, Doug [5 ]
Zwierzyna, Magdalena [5 ]
机构
[1] GlaxoSmithKline, Adv Biostat & Data Analyt, Brentford, England
[2] GlaxoSmithKline, Adv Biostat & Data Analyt, Collegeville, PA USA
[3] GlaxoSmithKline, Nonclin & Translat Stat, Stevenage, Herts, England
[4] GlaxoSmithKline, Res Stat, Stevenage, Herts, England
[5] GlaxoSmithKline, Stat Data Sci, Brentford, England
[6] GlaxoSmithKline, Res Stat, Collegeville, PA USA
来源
关键词
Bayesian hierarchical model; COVID-19 forecast model; Data science; Nonpharmaceutical interventions; Stochastic recruitment model;
D O I
10.1080/19466315.2021.2000487
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Contemporary clinical trials often have complex logistics: they are run across multiple centers/countries and involve a lot of uncertainties about disease prevalence rates, patient characteristics and regulatory requirements, all of which can vary across countries. As a result, planning and delivering such studies on-time has long been recognized as a challenge in the pharmaceutical industry. One well-known approach to modeling recruitment in complex trials, which we use as a starting point of our work is a Poisson-Gamma stochastic model. COVID-19 pandemic brought additional layer of complexity to recruitment modeling: as many countries went into shutdown, sponsors were forced with the dilemma of replanning study delivery rebalancing their portfolios "on the fly." That translated into the need to adapt the recruitment model to account for effect of COVID-19. In this work we present an approach that blends Poisson-Gamma model, real-time recruitment data updates and epidemiological modeling of COVID-19 spread. At the core of the methodology is sophisticated Bayesian hierarchical model predicting how pandemic intensity affected parameters of Poisson-gamma model. We also build an app conveniently showing many publicly available COVID models in one place. The work is a result of intense collaboration among many statisticians, data scientists and clinical operations professionals.
引用
收藏
页码:67 / 79
页数:13
相关论文
共 50 条
  • [41] IMPACT OF THE COVID-19 PANDEMIC UPON THE OPHTHALMOLOGICAL CLINICAL PRACTICE
    Dascalu, Ana-Maria
    Tudosie, Mihail Silviu
    Smarandache, Gabriel Catalin
    Serban, Dragos
    [J]. ROMANIAN JOURNAL OF LEGAL MEDICINE, 2020, 28 (01): : 96 - 100
  • [42] The impact of the COVID-19 pandemic on neurofibromatosis clinical care and research
    Heather B. Radtke
    Bonita P. Klein-Tasman
    Vanessa L. Merker
    Pamela Knight
    Nicole J. Ullrich
    Justin T. Jordan
    Bruce Korf
    Scott R. Plotkin
    [J]. Orphanet Journal of Rare Diseases, 16
  • [43] Impact of the COVID-19 pandemic on pediatricians' clinical activity in Cameroon
    Enyama, D.
    Chelo, D.
    Njinkui, D. Noukeu
    Kouam, J. Mayouego
    Puepi, Y. Fokam Djike
    Nkwele, I. Mekone
    Ndenbe, P.
    Nguefack, S.
    Nguefack, F.
    Koum, D. Kedy
    Tetanye, E.
    [J]. ARCHIVES DE PEDIATRIE, 2020, 27 (08): : 423 - 427
  • [44] The impact of the COVID-19 pandemic on neurofibromatosis clinical care and research
    Radtke, Heather B.
    Klein-Tasman, Bonita P.
    Merker, Vanessa L.
    Knight, Pamela
    Ullrich, Nicole J.
    Jordan, Justin T.
    Korf, Bruce
    Plotkin, Scott R.
    [J]. ORPHANET JOURNAL OF RARE DISEASES, 2021, 16 (01)
  • [45] Oncology clinical trial disruption during the COVID-19 pandemic: a COVID-19 and cancer outcomes study
    Bakouny, Z.
    Labaki, C.
    Bhalla, S.
    Schmidt, A. L.
    Steinharter, J. A.
    Cocco, J.
    Tremblay, D. A.
    Awad, M. M.
    Kessler, A.
    Haddad, R., I
    Evans, M.
    Busser, F.
    Wotman, M.
    Curran, C. R.
    Zimmerman, B. S.
    Bouchard, G.
    Jun, T.
    Nuzzo, P., V
    Qin, Q.
    Hirsch, L.
    Feld, J.
    Kelleher, K. M.
    Seidman, D.
    Huang, H.
    Anderson-Keightly, H. M.
    El Zarif, T.
    Abou Alaiwi, S.
    Champagne, C.
    Rosenbloom, T. D.
    Stewart, P. S.
    Johnson, B. E.
    Trinh, Q.
    Tolaney, S. M.
    Galsky, M. D.
    Choueiri, T. K.
    Doroshow, D. B.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 (08) : 836 - 844
  • [46] Predicting the Size and Duration of the COVID-19 Pandemic
    Lewis, Ted G.
    Al Mannai, Waleed, I
    [J]. FRONTIERS IN APPLIED MATHEMATICS AND STATISTICS, 2021, 6
  • [47] Impact of the COVID-19 Pandemic on Conduct and Results of CLEAR Outcomes Trial
    Singh, Abhayjit
    Laffin, Luke J.
    Sarraju, Ashish
    Lincoff, A. Michael
    Nicholls, Stephen J.
    Bloedon, Leanne
    Sasiela, William J.
    Li, Na
    Robinson, Paula
    Kelly, Stephanie
    Mason, Denise
    Nissen, Steven E.
    [J]. CLINICAL CARDIOLOGY, 2024, 47 (08)
  • [48] Predicting the COVID-19 pandemic in Canada and the US
    Chu, Ba
    Qureshi, Shafiullah
    [J]. ECONOMICS BULLETIN, 2020, 40 (03):
  • [49] Global Association of the COVID-19 Pandemic With Pediatric Clinical Trial Publication
    Grantham-Hill, Sarah
    Eyre, Michael
    Ramanan, Athimalaipet V.
    Modi, Neena
    de Wildt, Saskia N.
    Lim, Ming
    [J]. JAMA NETWORK OPEN, 2023, 6 (07)
  • [50] Sustained cancer clinical trial activity during the COVID-19 pandemic
    Bayle, A.
    Baldini, C.
    Romano, P. Martin
    Michot, J-M.
    Champiat, S.
    Bahleda, R.
    Gazzah, A.
    Marabelle, A.
    Verlingue, L.
    Geraud, A.
    Morel, D.
    Michiels, S.
    Ribrag, V.
    Hollebecque, A.
    Albiges, L.
    Besse, B.
    Soria, J-C.
    Massard, C.
    Barlesi, F.
    Postel-Vinay, S.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S1151 - S1151